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Summary.-The toxicity produced by two courses of methotrexate separated by
different intervals has been studied in matched groups of rats. The maximum
degree ofneutropenia reached when courses were separated by8 days or more wasno
greater than that seen after a single course of methotrexate. However, when courses
were separated by < 8 days, significantly greater neutropenia resulted. The degree
ofneutropeniafollowing the second course of methotrexate wasdirectly related to the
level of depression of bone marrow cell numbers at the time of the second course.
Conversely the anti-leukaemic effects of 2 courses of methotrexate, in terms of time
of onset of leukaemia and time of death in rats transplanted with a syngeneic T-cell
leukaemia, are shown to be similar when courses of methotrexate are separated by
between 2 and 12 days. Thus in this system, chemotherapeutic schedules using
methotrexate may be designed on the basis of minimal host toxicity without pre-
judicing anti-leukaemic effects.
These results are discussed in relation to toxicity and anti-leukaemic effects
observed during UKALL trials of treatment in acute lymphoblastic leukaemia.
METHOTREXATE (MTX) is one of the
main chemotherapeutic agents used in the
maintenance ofremission in acute lympho-
blastic leukaemia (ALL). It is a synthetic
analogue of folate and binds strongly to
dihydrofolate reductase (Bertino, Hillcoat
and Johns, 1967; Blakley, 1969). One of
its principal modes of cell killing is
assumed to be due to thymidine depri-
vation (Borsa and Whitmore, 1969). Its
inhibition of dihydrofolate reductase pre-
vents the methylation of several meta-
bolites, in particular the methylation of
deoxyuridine monophosphate to form
thymidine monophosphate, which is neces-
sary for DNA synthesis and replication.
Thus, by interfering with nucleic acid
synthesis, MTX, like most cytotoxic drugs,
primarily affects rapidly dividing cells.
However, the multiplicity of action ofthis
drug is well illustrated by the work of
Tattersall, Brown and Frei (1975) who
showed that MTX toxicity to mice could
be reduced by the administration of
thymidine, whilst its anti-tumour activity
was relatively unaffected.
Inacutelymphoblasticleukaemia,MTX
was initially used alone (Acute Leukaemia
Group B, 1969; Nagao, Lampkin and
Mauer, 1970) or in sequential therapy
(Acute Leukaemia Group B, 1961;
Saunders, KauderandMauer, 1967; Krivit
et al., 1968). Now it is usually given for
the maintenance of remission in combina-
tion with other drugs in cyclic therapy, as
for example in the St. Jude's programme
(Aur and Pinkel, 1972) and the Medical
Research Council's UKALL trials (Work-
ing Party on Leukaemia in Childhood,
1975 and 1976). In the UKALL Trials I
and II, the only major differences in
treatment were in the timing of 6-
mercaptopurine and MTX administration.
In the UKALL I trial, MTX was given
Correspondence to Dr Harding, Nuffield Department of Clinical Medicine, Radcliffe Infirmary, Oxford.
This work was supported by a Leukaemia Research Grant.VARIABLE INTERVALS BETWEEN METHOTREXATE COURSES
daily for 5 days, with an interval of 9 days
before the next course. In the UKALL
II trial, MTX was given daily for 5 days,
with an interval of 3 weeks before the next
course. This difference in treatment had
marked clinical effects: in the UKALL I
trial, patients developed neutropenic epi-
sodes, and there were deaths in complete
remission from pyogenic infections; in the
UKALL II trial, there was prolonged
lymphopenia with relatively little neutro-
penia, and deaths in complete remission
tended to be from viral, rather than
bacterial, infections (Working Party on
Leukaemia in Childhood, 1976). One of
the factors to which these different effects
may be attributed is the length of time
between courses of MTX.
Vogler, Mingioli and Garwood (1973)
have documented a phase of accelerated
myelopoiesis after MTX. The purpose of
our present studies was to determine
whether giving MTX during such a period
of increased myeloid cell production
resulted in greater myelosuppression than
that caused by MTX given at other times.
This was assessed by the effects on blood
neutrophil numbers of different intervals
between courses of MTX. These results
were related to the kinetics of the bone
marrow during recovery from a single
course of MTX.
Following on from the first part ofthis
study, we assessed the anti-leukaemic
effects of two courses of MTX, and
whether a good anti-leukaemic effect could
be obtained with courses of MTX spaced
sufficiently far apart to avoid cumulative
myelotoxicity.
MATERIALS AND METHODS
Animals.-Adult Fl hybrid rats of Agus
xPVG/c parents were used in all experiments.
In each series of experiments, animals w"ere
matched for sex, age and weight.
Methotrexate treatment.-MTX (Lederle)
ofa single batch was used in each experiment.
The plasma half-life of MTX is less than 1 h
and the majority is excreted in the urine
(Berlin et al., 1963). About 85-100% is
recoverable in the urine 12 h after an oral
dose of MTX (Delmonte and Jukes, 1962).
Thus we selected as a single course of MTX,
3 i.p. injections given at 12-h intervals as
likely to provide a suitable effect. In
preliminary experiments, we determined the
lowest in vitro concentration of MTX which
would give maximum inhibition of deoxyuri-
dine incorporation into bone marrow cells.
This concentration was found to be 10-6M,
which corresponids to a dose of 0 05 mg/
100 g body weight, assuming evendistribution
of MTX throughout the tissues.
The studies enumerating bone marrow cell
numbers were performed using a dose of
0 08 mg/100 g body weight/injection. The
experiments studying the toxic and anti-
leukaemic effects of the interval between
courses wereperformedusingdoses of0 05 mg/
100 g body weight/injection (moderate dose)
and 0 1 mg/100 g body weight/injection (high
dose).
Transplantable leukaemia.-The trans-
plantable rat leukaemia (NDM 10) which was
kindly supplied to us by Drs Ford and Roser
and which is syngeneic in PVG/c rats, grows
in the peritoneal cavity as an ascites tumour.
It enters a leukaemic phase, and metastisizes
to other body organs approximately one week
after i.p. inoculation with 107 cells. This
leukaemia is described by Dibley, Dorsch and
Roser (1975) as having some pathophysio-
logical similarity to human acute lympho-
blastic leukaemia. The experimental ani-
mals were given 107 NDM 10 cells i.p. 3 days
before the first course of MTX. The rats
challenged in this way have 100% mortality
at 2-3 weeks unless treated.
Bone marrow counts.-Bone marrow
samples were obtained from the femora of
experimental rats by removing the ends and
blowing out the bone marrow under pressure
from a CO2 cylinder delivered through a
Pasteur pipette. The bone marrowv was then
weighed before resuspension in Hepes buf-
fered basal minimum essential medium and
counting in white-cell counting fluid byphase-
contrast microscopy.
Blood white cell counts.-Blood samples
were taken daily between 9 am and 12 pm
from the tail veins ofexperimental rats. The
blood samples were dilutedinwhite-cell count-
ing fluid, and neutrophils, and total white
blood cells were enumerated byphase contrast
microscopy. Values are given as international
units, i.e. x 109/1.
Statistics. In the myelotoxicity studies,
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log1o means are given, following the practice
ofGalton (1969). However, geometric means
(the anti-log of the log means) are also
included in the Tables for convenience. In
survival studies in rats with leukaemia,
medians are given in the Tables. Statistical
analyses ofprobabilities were made using the
non-parametric Wilcoxon Rank Sum Test.
RESUILTS
The effects of a single moderate course of
MTX on bone marrow cells and peripheral
blkod neutrophil.
There is a significant depletion of bone
marrow cells/mg between Days 2 and 5
following a single course of MTX. Re-
coverv occurs between Days 6 and 10
(Fig. 1). The effect of this depletion of
bone marrow cells is reflected in a fall in
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The effects of the interval between two
moderate-dose coursesofMTXonsubsequent
neutropenia.
Table I summarizes the main results
of these experiments, giving the mean
maximum degree of neutropenia induced
by 2 MTX courses separated by different
intervals, and the mean maximum %
weight loss recorded in the same groups.
Fig. 2, however, records the results of 1
1 2 * 6 a I8 12 14 16 1a
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FIG. 2.-Blood neutrophil counts following a
single course ofMTXand 2 courses ofMTX
separated by 7 days. Curves represent the
mean of log,, values and there are 5
observations for each point.
-.j < _ __ group where MTX courses were separated
by 7 davs in more detail. It will be seen
/ that, 2 days following the start of the
MTX second course, there is a rapid rise in
_tt _ neutrophil count, which is considerably
0 2 * 6 S is 12 14 more marked than the recovery seen
DAYS POST SINGLE COURSE MTX after a single course. Presumably, this
--Neutropenia and bone marrow cellu- largely results from a rapid release of
, following a single course of 31TX. pre-formed neutrophils from the bone
point represents the log mean of 3 marrow. This rapid rise is followed by a
als for bone marrow studies and 5 rpd by
als for the neutrophil studies. The profound and sudden drop i neutrophl
ts are significantly different from the 9 numbers which is maximal at Day 13.
rols for bone marrow cells per mg on After this, recoverv occurs rapidly, to
2 to 5. reach normal levels by Day 15, following
Leutrophil numbers between Days which there is a consistent overshoot in
11, the maximal depression being whichneutrophil countsrise above normal.
s 7 and 8. The recoverv in bone This overshoot is recorded for the various
cellL numbers between Davs 6 and intervals between courses in Table II.
t only due to increased rate ofbone Table I shows that a single course of
cell division, as the fall in peri- MTX has little or no effect on the weight
blood neutrophil count between of rats. However, there is significant
and 11 clearly indicates that depression ofbodyweight when the second
of bone marrow cells is markedly course ofMTX is given on Days 2, 3, 5, or
over this period. 6. When the second course of MTX is
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separated by more than 6 days (i.e. on
Days 7, 9, 11 or 14) the weight change is
no longer significant. The lowest weights
were generally recorded 4 days after the
second course of MTX (see Table I). These
calculations were made on the basis ofthe
lowest recorded weight, compared with
initial bodyweight, throughout the experi-
ment, so daily fluctuations in body weight
will account for minor weight losses.
The neutropenia data show a similar
picture. When the second course ofMTX
is given on Days 2-7, there is statistically
significant neutropenia compared with
that produced by a single course of MTX.
When the second course of MTX was
given on Days 8-21, there was no signifi-
cant depression of neutrophil counts com-
0*4
0- 2 Mean bone marrow leukocytes/mg bone marrow
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FIG. 3. Correlations between bone marrow
celltlarity following a single course of MTX
and maximum neutropenia following two
courses of MTX at various intervals.
pared with that produced by a single
course of MTX. When the second course
was given on Day 10, there was significant
elevation compared with a single course.
The greatest neutropenia generally occur-
red 6 days after the second course ofMTX
(Table I).
When the level ofneutropenia obtained
at various intervals between courses is
compared with bone marrow cell numbers/
mg bone marrow (Fig. 3) it can be seen
that increased neutropenia is associated
with second courses of MTX at any time
during the period when bone marrow
numbers are reduced by the first course:
i.e. superadditive effects on blood neutro-
phils occur, not only during recovery of
bone marrow numbers, but also during
the initial period when bone marrow
numbers are falling.
The overshoot in neutrophil recovery
described in relation to Fig. 2 is tabulated
for all groups of rats in Table II. An
interesting point arising out of this Table
is that significant reactive neutrophilia
occurs in double courses separated by
2-10 days, whereas superadditive neutro-
penia is only seen in courses separated by
2-7 days. The time of the maximum
neutrophil count is shown in Table II,
and was generally 9 days after the second
course of MTX. In this respect it would
appear that measurement ofthe late over-
shoot in neutrophil counts following
second MTX courses is the most sensitive
method we have found for detecting a
superadditive effect.
The effect of a third course of MTX, given
21 days after the previous course, on blood
neutrophil counts
The previous section showed that a
3-week interval between a first and second
course of MTX resulted in identical
changes in blood neutrophil counts after
each course. To see if the increased
neutrophil depression observed after
double MTX courses would have a long-
term effect on the susceptibility of the
bone marrow myeloid cells to MTX, some
of the groups of rats described in the
previous section were subjected to a third
course of MTX, 3 weeks after they had
received their second course. The results
are shown in Table III. These indicate
that by 3 weeks recovery had occurred in
all groups, and that a further course of
MTX at that time produced the same
pattern of neutropenia as that seen after
a single course.
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TABLE II.-Mean Values for Late Reactive Neutrophilia
Group
Controls
MTX Day 0 oinly
Days 0+2
Days 0d- 3
Days 0+4
Days 045
Days 0+ 6
Days 0+ 7
Days 0-k 8
Days 0+9
Days 0+10
Days 0+11
Days 0+ 14
Mean oflog1o
counts
0 43
0 40
0-78
0-78
0-67
0-61
0.59
0-76
0 93
0-72
0 70
0 53
0-58
+ s.d.
0 053
0-100
0-138
0-213
0 228
0 075
0-067
0-149
0 214
0-140
0-117
0-119
0-138
n
5
5
5
6
5
5
5
6
4
6
6
5
4
Geometric
mean
2-69
2 -51
6-03
6-03
4-68
4 07
3-89
5-75
8 -51
5 -25
5-01
3-39
3 80
P
(vs. Day 0 only)
0*5
0-001
0-01
0 05
0-01
0-01
0-01
0-01
0*01
0-01
0-1
0 05
Day ofgreatest
neutrophil
count
12
11
12
12
14
15
16
20
18
21
21
26
All rats, iineluding the controls, were counted on each day. The figures in Columns 2 and 5 represent the means of the highest neutrophil counts recorded for each animal.
The day upon which the highest neutrophil count was recordedl was generally 9 days followxing the last couirse of MTX. Counts recorded as i.u. (x 109/1) or log10 i.u.
TABLE III. Maximum uNeutropenia after a Third Course of Methotrexate
Group
MTX Day 0 only
Days 0+21
Days 0+2+21
Days 0+3d-24
Days 0+4+25
Days 0+54- 26
Days 0+6+27
Days 0+7+28
MTX Day 0 only
All groups given MTX
21 days after previous
course
Mean oflog1o
counts
-91
193
174
194
168
184
175
187
-L s.d.
0-20
0 07
0-25
0-16
0-31
0-08
0-26
0 39
n
5
5
5
6
5
5
5
5
Poolinig All Available Data
186 0 258 34
I77
Geometric
mean
0-81
0-85
0 55
0-87
0-48
0-69
0 56
0 74
p
(vs. Day 0 only)
0 9
0 3
0 9
0 2
0 7
0*4
0-8
0-72
0-216 36 0-59 0*2
Counits are showni a.s i.u. ( x 109/1) or log10 i.u.
The effect of large-dose courses of metho-
trexate
When a large dose of MTX is given
(0.1 mg/100 g body weight/injection) the
results obtained are somewhat different.
The major difference observed was that
there were deaths associated with a second
course of MTX given on Days 2-5 (Table
IV). The greatest weight loss and mor-
tality was seen when the second course of
MTX was given on Day 4. The effects of
moderate dose courses of MTX at this
interval were relatively small in relation
to loss of body weight (Table I).
The blood neutrophil data show that
the most profound neutropenia occurs
when the second course of MTX is given
on Days 3 or 4 instead ofDay 6. Because
of the small numbers of rats used in this
experiment, the neutropenia associated
with a second course of MTX does not
reach statistically significant levels when
compared with a single course of MTX.
The time of maximum neutropenia was
also more variable, ranging from 4 days
(0+ 2) to 9 days (0 + 9). However, all
groups, including that given a single
course ofMTX, must be regarded as being
at risk of infection. This may account
for the mortalities occurring in this experi-
ment. Pathological examination of rats
showed anaemiawithmarkedlunghaemor-
rhages. In addition, histological exami-
nation of the lungs demonstrated bacterial
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infection. Macroscopic examination of
the gastrointestinal tract did not reveal
pathological changes and haemorrhage,
although this has been reported as being
associated with mortality at 4-5 days
following a large single dose of MTX
(Vitale et al., 1954).
Blood and bone marrow leucocyte counts
followving i.p. injedion of leukaemia celle
Fig. 4 shows the log1o deviation from
control of total white blood cells, blood
neutrophils and bone marrow cells/mg
when no MTX is given.
DAYS POST TUMOUR IhOCULATIOP
FIG. 4. The effects on bone marrow cell
nuimbers, total white blood cell numbers
and blood neutrophil nmIrbers of an i.p.
inoculation of 10 N>DM 10 cells. By 17 days
after the inoculation the tumour cells, 5/9
rats had died. See Table V for details of
survival.
These values are within normal limits
up to Day 7, when the blood counts
become elevated. This elevation is due
to both the appearance of leukaemic cells
in the blood, and to a marked rise in
granulocytes. Between Days 9 and 14,
the number of bone marrow cells per mg
weight of bone marrow becomes signifi-
cantly depleted. Thus, it seems reason-
able to assume that the rapid increase in
blood neutrophil numbers is mainly due to
release of cells from the bone marrow.
The trigger for this release has not been
determined. The total white blood cell
count increases until the death of the
animal, when it has reached levels of
200-600 x 109/1. The neutrophil count
is elevated up to Day 12, when there is a
reversal, and the count rapidly decreases;
and at death the neutrophil count is very
low when, because of the extremely high
total count, neutrophil numbers are dif-
ficult to estimate accurately.
The effect of MTX on theprogre&s of tran8-
planted leukaemia
When MTX is administered, the onset
ofleukaemia, as determined by the time at
which the total white blood cell count
reaches 30 x 109/1, isdelayed, andsurvival
is extended. An example of a typical
experiment is shown in Fig. 5. The onset
of leukaemia is extended from Day 9 to
DAYS POST MTX
3 5 7 X 11 13 15 17 it 21 23 25
DAYS POST TUMOUR l%OCUlATIOP
FIG. 5.-An example ofthe delay in the onset
ofleukaemia and extension ofsurvival time
due to the adminition of two courses of
MTX separated by 3 days. The onset of
leukaemia was delayed by 7 days, and the
survival time was extended by 10 days.
46
0
X
a
u
0X
ff
0
Z
Z.
gm
2
C.-
dVARIABLE ILNERVALS BETWEEN MEHOTREXATE COURSES
a~~~~~
C _C0c 0 0 4
CB t 00 Cb~~
C
Io o ooo 0
V V
= o s 0 0 CO e X
.5 o0 ct 0 rt0
X
a.. . ..... 0
CD 10 4i~~~~~~~~~~~~~5
t- o e _0_- - go AO 0,,,o~~~~~~ V,~~~~~~~,f
>~, CDq = .0 0
Co o
0 I e I Ct>Xs P*' 4' 00
Co oi oo o
C)
°e CB
o~~~~~ v
Al
° 0 P
0Z ._ C
0 C
C) C c0 4= 0 rW t X0 CD
o~~~~~~ 0 3
V 0
ti m 0 o o asr0 0°
0 CB Ca CB as co PC _
o0.~s0 00r...4tqcs co o E
an CO 004nC''C 'eC 4.4
47
.0
* 0
O
0
o
_~
.> 0
0;
O 0
w
*> a
;V
0
._
'0
0
2
~ 0
0
4
I
0-4
PA
04
P.
...4
E-4B. HARDING, J. CULVENOR AND I. C. M. MAcLENNAN
TABLE V.-The Onset of Leukaemia and Survival with Different MTX Schedules
Experiment 1
No MTX
MTX Day 0 only
Days 0+2
Days 0+3
Days 0+4
Days 0+5
Days 0+6
Experiment 2
No MTX
MTX Days 0+3
Days 0+7
Days 0+9
Days 0+12
Onset ofleukaemia (Days)
8
13
13
15
12
13
14
8
15
14
12
13
8
13
14
15
14
13
14
9
15
15
12
13
9
13
14
15
15
13
15
9
16
16
12
13
9
14
I+'. 16*
16
164
16
9
17
16
12
14
10
14
15
17
15
21
17
20
14
Median Survival (Days)
9
13
14
15
14 5
13
14*5
9
16
16
12
13
13
19
20
23
21
20
22
18
24
22
22
20
14
19
21
23
22
21
22
19
24
22
23
23
14
20
23
24
23
21
22
19
25
23
23
23
14
20
23
24
24
22
23
19
25
24
25
24
Day 16, and the survival from Day 14 to
Day 24. Also shown in Fig. 5 is the fact
that the neutrophil count is still reduced
on Day 9 after a single course of MTX,
which is presumably due to the myelo-
toxicity of MTX described previously.
The onset of leukaemia, and survival
times for other MTX schedules is shown
inTable V. Table VI shows the statistical
significance (in terms of probability, P)
ofthe results in Table V. In Experiment
1, the onset of leukaemia is significantly
delayed by a single course of MTX, but
significant further delay was not achieved
by additional courses of MTX, except
when the second course was given at
Day 3. The administration of a second
course of MTX significantly extends
survival in all cases, except where the
courses were separated by 5 days. In the
second experiment, course intervals of 7, 9
and 12 days are compared with MTX on
Days 0 and 3. MTX on Days 0 and 12 is
associated with earlier onset ofleukaemia.
However, the spacing of courses of MTX,
within the limits of these experiments,
does not appear to be critical in terms of
survival.
Thus, MTX given in two courses
separated from 2 to 12 days is equally
effective in this respect. However, the
onset of leukaemic phase appears to be
most effectively delayed by MTX on
Days 0 and 3.
DISCUSSION
Vogler et al. (1973) showed similar
bone marrow kinetics in mice after a single
dose of MTX. They found that a single
TABLE VI.-Statistical Analysts (Probabilities) of the Onset ofLeukaemia and
Survival Time (Data in Table V)
Experiment 1
No MTX
MTX Day 0 only
MTX Days 0+2
Days 0+3
Days 0+4
Days 0+5
Days 0+6
Experiment 2
No MTX
MTX Days 0+3
Days 0+7
Days 0+9
Days 0+ 12
Time to reach 30 x 103
WBC V8. MTX Day 0 only
0-01
0*3
0-02
0-2
0-*99
0-1
Survival vs. MTX
Day 0 only
0-02
0 05
0*02
0-05
0-1
0-02
Time to reach 30 x 103
WBC v8. MTX Days 0+3
0-01
0 7
0*1
0-02
Survival vs. MTX
Days 0+3
Not analysed
0-02
0-3
0 3
0-2
0 05
Survival v8. MTX
Days 0+3
0*02
0-1
0 3
0-1
15
21
24
26
23
27
25
26
25
Median
14
20
23
23
22*5
21
22
19
25
23
23
23
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dose of 60 mg/kg caused a reduction in the
proliferating bone marrow pool to 43% of
control on Day 2, which returned to
initial levels by Day 6 (cf. Fig. 1). When
they repeated the dose of MTX on Day 3,
at a time when they had demonstrated
that the number of colony-forming cells
was elevated, there was a fall in the
proliferating pool to 8% of the control
value. This result compares well with
our results showing that large-dose courses
ofMTX at 3- or 4-day intervals resulted in
maximal neutropenia, whereas neutro-
penia when the second course was given at
Day 8 did not result in greaterneutropenia
than seen after a single course ofthe drug
(Table IV).
Following a second dose on Day 3,
Vogler et al. (1973) demonstrated a nine-
fold increase in colony-forming cells on
Day 5. This may be analogous to our
results showing marked polymorpho-
nuclearleucocytosis inratsgiven moderate
dose treatment with the second course
given on Days 2-4 (Table III). Although
the numbers of rats surviving in the high-
dose experiments were too small to allow
a confident statement about the degree of
reactive neutrophil leucocytes, it is
interesting to note that neutrophil counts
above 40 x 109/1 were recorded in 2 rats
surviving after second courses on Days 3
and 4. This hints that the degree of over-
shoot may relate to the degree of neutro-
penia induced. Such a conclusion was
drawn byMorley et al. (1971), who showed
that colony-stimulating factor levels in
irradiated mice were directly proportional
to the degree ofneutropeniainduced. Such
a clear-cut relationship, however, is not
supported by the fact that reactive poly-
morphonuclear leucocytes occurred in rats
given second doses of drug between 8 and
10 days when no superadditive neutro-
penia was seen. In fact, the overshoot of
neutrophil counts after second courses on
Days 8and 9werehigherthanany recorded
following the shorter-spaced double doses
which caused most marked neutropenia.
If one considers the bone marrow
studies, there is a close correlation between
the degree ofsubsequent neutropenia and
the reduction in bone marrow cell numbers
at the time of the second course of MTX
(Fig. 3). It is impossible, from our
studies, to draw any conclusions about the
rate of division of single cell types within
the bone marrow, and such data might
correlate morecloselyAwith theneutropenia
induced by a second course ofMTX.
However, it is clear that MTX has its
effects on the myelocyte, which has a
maturation time of some 5-6 days before
appearing in the blood as a neutrophil,
rather than on the stem cell, which would
not show an effect for 10-12 days (van
Furth, 1974).
Thus there is aperiod ofsome 5-6 days
during which the normal myelocyte popu-
lation is re-formed, and during which few
neutrophilsappearintheblood. Thismay
be seen in Fig. 1. When cells are lost
from the myelocyte pool, a significant
number of precursor cells become myelo-
cytes (Craddock, 1973). It may be that
superadditive effects in part relate to the
length of time and the amount of MTX
which persists in myeloid precursors, as
well as to the rate ofproliferation by these
cells. We have performed experiments
to assess the effect ofMTX on rats under-
going increased neutrophil production as a
result of experimentally induced pyelo-
nephritis. These studies indicated that
there was not a simple correlation between
MTX-induced neutropenia and the rate of
prQduction of neutrophils (Harding and
MgcLennan, to be published).
Finally, one may ask what are the
points one can gain from this study which
may be of help in minimizing myelo-
toxicity following multiple MTX courses
in man? Clearly the persistency ofsuper-
additive toxicity will vary with the dose
given and the length of courses. Also the
dose response in man is unlikely to be the
same as in rats. However, it is reasonable
toconclude that superadditivetoxiceffects
ofrepeat doses ofMTX can be avoided by
increasing the spacing between courses: a
day or two one way or the other can make
a great deal of difference. For example,
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the severe superadditive neutropenia
occurs when courses are separated by 7
days, while the additive effect is negligible
when 8 days are allowed to elapse between
courses. It is clear that toxicity cannot
be avoided by reducing the spacing
between courses, so that a second dose is
given when bone marrow proliferation is
most depressed.
The data presented here are compat-
ible with the conclusion that the marked
myelotoxicity of the Medical Research
Council's UKALL I trial related to the
close spacing of 5-day courses of MTX
(M.R.C. Working Party, 1975). The rela-
tive lack of myelotoxicity in UKALL II,
where identical courses of MTX are
separated by 3 weeks (M.R.C. Working
Party, 1976) again accords with our data.
For our studies of the effects on the
antileukaemic activity of altering the
interval between courses ofMTX, we have
used as our model of acute lymphoblastic
leukaemia (ALL) a rat T-cell leukaemia
which has been described as having some
similar pathophysiological features to
human ALL (Dibley et al., 1976). How-
ever, in terms of cell division times and
the proportion of cells in cycle, this rat
leukaemia is different from human ALL.
The rat leukaemia has a particularly rapid
doubling time of 1 day (unpublished
results), with a survival time of only 2-3
weeks following i.p. injection of 107
leukaemic lymphoblasts. In human ALL
the leukaemic cells are not as rapidly
dividing, and undergo division at a rate
similar to or less than normal cells in
the bone marrow: the mean generation
time in ALL patients has been estimated
as being 2-8 days (Clarkson, 1969).
Thus it is possible that MTX, which
principally affects active or dividing cells,
would have a different anti-leukaemic
effect in patients from that in the rats of
our studies. However, leukaemic cells pro-
liferate faster when many cells have been
killed by therapy and their concentration
has been reduced (Clarkson, 1969).
Hryniuk (1972) showed that the anti-
leukaemic effects ofMTX are proportional
to the rate of cell proliferation. On these
grounds MTX is more likely to be an
effective drug in the maintenance of
remission, which is the situation we have
simulated in our experiments. Skipper
et al. (1957) showed a correlation between
inoculum size and curability with MTX,
under favourable conditions. It was sug-
gested that this was due to the mutation
rate of leukaemic populations resulting
in MTX resistance. Although the anti-
leukaemic effects we have observed
are similar over a range of treatment
schedules, the best long-term schedule
would be one based on minimal host
toxicity. Goldin et al. (1956) showed in
mice that the best schedule for early
therapy is infrequent heavy doses of MTX
(in his studies, every 4 days rather than
daily). The same authors (Goldin et al.,
1954a) had earlier shown that the greatest
anti-leukaemic effects were obtained with
multi-dose schedules (Days 2 + 4 + 6).
However, these were achieved at the cost
of high mortality from host toxicity.
They overcame this problem by using
even higher doses of MTX, with admini-
stration of Citrovorum factor 12 h after
the administration of MTX (Goldin et al.,
1954b). Tattersall et al. (1975) reduced
MTX host toxicity by thrice daily admini-
stration of thymidine, without inhibiting
the anti-tumour effects. In our present
study, blood neutrophils are depressed to
an extent greater than that caused by a
single course of MTX if a second course of
MTX is given on Days 2 to 7, but not if
given after 8 or more days. We also show
that body weight is depressed ifthe second
course ofMTX is given on Days 2 to 6, but
not if given later. However, the anti-
leukaemic effects of MTX courses sepa-
rated by 2 to 12 days are similar, and thus
the courses could be spaced to give
optimum anti-leukaemic effects with mini-
mal host toxicity.
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